Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
| Autor: | Satoru Takada, Yoshifusa Takatsuka, Kiyotoshi Imai, Yukihiko Kimura, Yukiyoshi Moriuchi, Yasushi Miyazaki, Keitaro Matsuo, Noriko Usui, Shuichi Mizuta, Tomoya Maeda, Sigehisa Tamaki, Hideki Akiyama, Toshiaki Yujiri, Akira Yokota, Heiwa Kanamori, Kazunori Ohnishi, Shigeki Ohtake, Yoshihiro Hatta, Tomoki Naoe, Yasunori Ueda |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Prognostic factor Chemotherapy medicine.medical_specialty Multivariate analysis business.industry medicine.medical_treatment Complete remission Imatinib Hematology Hematopoietic stem cell transplantation Minimal residual disease imatinib hemic and lymphatic diseases Internal medicine Immunology medicine Original Article In patient allogeneic hematopoietic stem cell transplantation prognostic factor business philadelphia chromosome-positive acute lymphoblastic leukemia medicine.drug |
| Zdroj: | Blood Cancer Journal |
| ISSN: | 2044-5385 |
| Popis: | We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) following imatinib-based therapy. Among 100 adult patients who were prospectively enrolled in the JALSG Ph+ALL202 study, 97 patients obtained complete remission (CR) by imatinib-combined chemotherapy, among whom 60 underwent allo-HSCT in their first CR. The probabilities of overall survival (OS) and disease-free survival (DFS) at 3 years after HSCT were 64% (95% CI, 49–76) and 58% (95% CI, 43–70), respectively. Prognostic factor analysis revealed that the major BCR–ABL transcript was the only unfavorable predictor for OS and DFS after HSCT by both univariate (HR, 3.67 (95% CI 1.49–9.08); P=0.005 and HR, 6.25 (95% CI, 1.88–20.8); P=0.003, respectively) and multivariate analyses (HR, 3.20 (95% CI, 1.21–8.50); P=0.019 and HR, 6.92 (95% CI, 2.09–22.9); P=0.002, respectively). Minimal residual disease status at the time of HSCT had a significant influence on relapse rate (P=0.015). Further study of the BCR–ABL subtype for the clinical impact on outcome of allo-HSCT in Ph+ALL is warranted. Blood Cancer Journal, 2(5), e72; 2012 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|